share_log

Biofrontera Doses First Patient in Phase 3 Actinic Keratosis Clinical Trial

Biofrontera Doses First Patient in Phase 3 Actinic Keratosis Clinical Trial

生物弗龍特在 3 期光化性角化病臨床試驗中劑量第一名患者
MT Newswires ·  2023/01/09 17:32

Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論